| Document |
Document Title |
|
JP3898757B2 |
Compounds of general formula (1) are described:wherein=W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl or -XRa group where X is -O-, -S(O)m- [where m is zero or an integer of value 1 or 2], or -N(Rb)- [where Rb is a hydrogen atom...
|
|
JP2007506717A |
Compounds of formula (I) or pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type IV (PDE4) and are of use in the treatment of inflammatory and/or allergic diseases.
|
|
JP2007502836A |
The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The pres...
|
|
JP3881165B2 |
To provide a method for producing a compound having high HIV activity. A process for the preparation of enantiomerically pure β-D-(-)- dxoxolane-nucleosides (e.g. a compound represented by formula 2 when thymine is used as a base) compr...
|
|
JP3881516B2 |
A nociceptin receptor ORL-1 agonist is used in the manufacture of a pharmaceutical composition for the treatment of cough symptoms.
|
|
JP2007502332A |
The invention features certain compounds useful in the treatment of memory disorders, i.e., they reduce or delay memory loss or they enhance memory retention. Because certain of the compounds do not substantially inhibit either COX-1 or ...
|
|
JP2007502321A |
Compounds of general formula: Formula (I) wherein R1, R2, R3 and A are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therap...
|
|
JP2007500709A |
Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
|
|
JP2006528963A |
Compounds of general formula: (I) wherein R1, R2, R3 and A are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in pa...
|
|
JP2006528659A |
This invention relates to nicotinamide derivatives of general formula (I) in which X, Y, n, Z, L and R have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions cont...
|
|
JP2006516572T5 |
|
|
JP3844978B2 |
To produce an analog of BCH-189 from a less expensive precursor. A method for resoluting the enantiomers of a nucleoside of the formula (wherein, Y is H or fluorine; and R is an acyl). The method includes a process treating a nucleoside ...
|
|
JP2006520759A |
The present invention relates to aniline derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
|
|
JP2006520794A |
The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivative...
|
|
JPWO2004092163A1 |
The present invention is based on the equation (1).(In the equation, R is a hydrogen atom or C which may be substituted.1-6Represents an alkyl group, A represents an imidazolyl group or a pyrazolyl group, and B represents a group represe...
|
|
JP2006516572A |
The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment o...
|
|
JP2006516271A |
Therapeutically active compounds of formula (I) or (II): wherein the variables in formulas (I) and (II) are defined in the description, and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na+/...
|
|
JPWO2004083186A1 |
formula:[In the formula, R1Represents a hydrogen atom, a ribofuranosyl group. R2Represents a protecting group for a hydrogen atom or a hydroxyl group. ], A therapeutic agent for chronic hepatitis C and an anticancer agent, which are admi...
|
|
JPWO2004078719A1 |
General formula (I)(In the formula, all symbols are as described in the specification.) Compounds and salts thereof. The compound represented by the general formula (I) is PGD.2Allergic diseases (allergic rhinitis, allergic conjunctiviti...
|
|
JP2006515624A |
The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2 R , 5 S , cis)-4-amino-5-flu...
|
|
JP3778929B2 |
Onium salts of taxo-diterpenoid-Cn,2-O-aza-arenes form water soluble self-assembling nanostructures above a critical aggregation concentration. The onium salt of aza-arene includes a delocalized charge which renders derivatized taxo-dite...
|
|
JP3778928B2 |
Onium salts of taxo-diterpenoid-C, 2-0-aza-arenes are employed as water soluble prodrugs. For example, taxol-2'-methylpyridinium tosylate (MPT) is characterized by an elevated aqueous solubility, rapid activation by serum protein, good s...
|
|
JP2006508997A |
This invention relates to pyrimidine derivatives of general formula (I) as inhibitors of kinases, their production as well as their use as medications for treating various diseases.
|
|
JP2006508134A |
A pharmaceutical composition comprising 3'-azido-3'-deoxythymidine and (2R,cis)-4-amino- 1 -(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one suitable for once daily administration
|
|
JP2005537228A |
This invention is directed generally to proteinase (also known as "protease") inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also kn...
|
|
JP3718737B2 |
To obtain a dihydroquinoline derivative having lowering action on blood sugar, useful for treating and preventing a diabetes as a hypoglycemic agent. This compound is shown by formula I (R1 is H or a halogen; R2 is H, a lower alkyl or ph...
|
|
JP2005533813A |
Disclosed herein are compounds of Formula I, or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine recept...
|
|
JPWO2004002973A1 |
Efficiently and industrially advantageous for optically active 1-substituted amino-2,3-epoxypropane, which is made from optically active 1-substituted amino-2,3-propanediol and is useful as a manufacturing intermediate for agricultural c...
|
|
JP3704055B2 |
To obtain a new intermediate useful for a method for diastereoselective synthesis for preparing optically active cis-nucleosides, nucleoside analogs and derivatives. This intermediate is represented by the formula (I), wherein, W and X a...
|
|
JP3702321B2 |
PURPOSE: To obtain the subject new derivative which is a specific 1,3-oxathiolane derivative, capable of manifesting excellent effects on clinically important aspergillosis or candidasis, having high safety and useful as an orally or an ...
|
|
JP2005521689A |
The application concerns a compound of formula Ia: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: Y is O; R 1 and R 2 together form, along with the nitrogen atom to which they are attached, an op...
|
|
JP2005520782A |
The present invention is directed to novel amide-containing compounds which have an improved solubility and a method of improving the solubility of amide-containing compounds. The amide-containing compounds include oxazolidinone compound...
|
|
JP2005520791A |
Disclosed are compounds of the formula wherein the variables RN, RC, R1, R25, R2, and R3 are as defined herein. These compounds have activity as inhibitors of beta-secretase and are therefore useful in treating a variety of disorders suc...
|
|
JP3659969B2 |
PCT No. PCT/EP94/02702 Sec. 371 Date Feb. 5, 1996 Sec. 102(e) Date Feb. 5, 1996 PCT Filed Aug. 12, 1994 PCT Pub. No. WO95/05366 PCT Pub. Date Feb. 23, 1995The present invention is concerned with compounds having the formula (I) the pharm...
|
|
JPWO2003070277A1 |
The present invention relates to the use of a compound having an agonistic activity to the cannabinoid receptor, a prodrug, a pharmaceutically acceptable salt or solvate thereof for the preparation of an antipruritic, wherein the compoun...
|
|
JP2005515176A |
The invention concerns quinazoline derivatives of Formula (I); wherein each of Q<1>, Q<2>, Z, R<1>, R<2>, R<3>, and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions conta...
|
|
JP2005514396A5 |
|
|
JP2005511603A |
The invention concerns quinazoline derivatives of Formula (I); wherein each of Q<1>, Q<2>, Z, R<1>, R<2>, R<3>, and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions conta...
|
|
JP3636044B2 |
To obtain a medicament for treating seborrhiasis of the skin and/or scalp, in particular acne and/or blackhead and/or comedo by including a specific dimethoxyindolecarboxylic acid and/or like. This medicament is obtained by including pre...
|
|
JP2005505604A |
Use of phosphodiesterase IV inhibitors and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment of osteoporosis, tumours, tumour metastases, atherosclerosis, rheumatoid arthritis, multiple scl...
|
|
JP2005504728A |
The invention relates to compounds of the formula (I) which exhibit activity as selective serotonin re-uptake inhibitors.
|
|
JP3621427B2 |
Agent for treatment or prevention of glomerulopathy comprise a sulphonamide derivative of formula R4-R3-SO2-N(R2)C(R1)COY (I) or its salt or hydrate. R1, R2 = H or optionally substituted lower alkyl, aryl, aralkyl, heteroaryl or heteroar...
|
|
JP2005500287A |
The present invention provides novel compounds represented by formula I: or pharmaceutically acceptable salts thereof useful for treating Flaviviridae viral infection.
|
|
JPWO2003020302A1 |
The present invention relates to an agent that suppresses the growth of lamivudine-resistant hepatitis B virus during long-term administration of lamivudine. By administering IFN-β to the YMDD mutant virus generated during long-term adm...
|
|
JP2004535428A5 |
|
|
JP2004531474A |
Symmetrically disubstituted aromatic compounds and pharmaceutical compositions containing such compounds that inhibit and/or modulate the activity of poly(ADP-ribose) glycohydrolase, also known as PARG, are described. The invention is al...
|
|
JP2004217553A |
To obtain a new germicidal insecticide which has high effect in a small amount on the insecticide and is highly safe to object crops.The hetero-iminophenyl compound is represented by formula (1) [A is a group represented by formula (2); ...
|
|
JP2004168706A |
To provide a bactericidal or insecticidal agent for agriculture and horticulture which is highly effective even when used in a small amount and which is highly safe for object crops.A phenyl carbamate compound represented by formula (1) ...
|
|
JP2004149543A |
To provide a enantiomerically pure dioxolane nucleoside having excellent anti-HIV activity.The method and a composition for therapeutic treatment of an infected human with HIV (human immunodeficiency virus) include administration of an H...
|
|
JP3530150B2 |
To obtain BCH-189 analog from an inexpensive precursor. This compound is represented by the formula (R is selected from hydrogen, an alkyl group, a silyl group and an acyl group) and is enriched with an enantiomer.
|
